Nuvation Bio is a pre-profitability biotech with a 26% short interest and put/call ratio of 9.0, but analysts project more than 140% upside and the company maintains a strong current ratio, leaving the risk-reward asymmetric and highly speculative.
Thesis pillars
- Analyst Upside Vs Short Pressure→Stable
- Cash Position And Current Ratio→Stable
- Obv Accumulation Recovery Setup↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 2, 2026· older than 90 days
Nuvation Bio Inc. (NUVB) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.73: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 13.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality; Below long-term trend.
Nuvation Bio is a global oncology company that commercially launched IBTROZI (taletrectinib), a ROS1 inhibitor for metastatic non-small cell lung cancer, in the U.S. in June 2025 following FDA approval, with taletrectinib also approved in Japan (marketed by partner Nippon... Read more
Sell if holding. Engine safety override at $4.73: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 13.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality; Below long-term trend. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — Nuvation Bio Inc.
Latest news
- NEWS Nuvation Bio Q3 2026 Earnings Call Transcript — benzinga Nov 4, 2026 neutral
- NEWS Nuvation Bio to present subgroup analyses at lung cancer conferences By Investing.com - Investing.com UK — Investing.com UK Aug 4, 2026 positive
- NEWS NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits — Stocktwits Aug 4, 2026 positive
- NEWS Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy? - Yahoo Finance — Yahoo Finance Aug 4, 2026 positive
- NEWS Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy? - finance.yahoo.com — finance.yahoo.com Aug 4, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:54:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductIBTROZI (taletrectinib)10-K Item 1A: 'IBTROZI is our only product approved for marketing by the FDA, and our ability to generate revenue from product sales and achieve profitability is mostly dependent on our ability'
- HIGHcounterpartyDaiichi Sankyo (in-license partner)10-K Item 1: 'Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), pursuant to which Daiichi Sankyo granted to AHT exclusive worldwide rights to develop and commercialize taletrectinib'
Material Events(8-K, last 90d)
- 2026-06-30Item 1.01LOWNuvation Bio completed a $250.0 million offering of 0.75% Convertible Senior Notes due 2032 and amended its Revenue Interest Financing Agreement with Sagard Healthcare Partners in connection with the offering; a routine capital-raise and financing amendment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.73: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 13.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality; Below long-term trend. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $4.40. Score 5.4/10, moderate confidence.
Analyst target: $11.31 (+139.1% upside). Prior stop was $4.40. Stop-loss: $4.40.
Concentration risk — Product: IBTROZI (taletrectinib); Concentration risk — Counterparty: Daiichi Sankyo (in-license partner); Quality below floor (3.9 < 4.0).
Nuvation Bio Inc. trades at a P/E of N/A (forward -315.3). TrendMatrix value score: 6.8/10. Verdict: Sell.
19 analysts rate NUVB, with a consensus score of 4.2/5. 11 analysts publish price targets averaging $13.
What does Nuvation Bio Inc. do?Nuvation Bio is a global oncology company that commercially launched IBTROZI (taletrectinib), a ROS1 inhibitor for...
Nuvation Bio is a global oncology company that commercially launched IBTROZI (taletrectinib), a ROS1 inhibitor for metastatic non-small cell lung cancer, in the U.S. in June 2025 following FDA approval, with taletrectinib also approved in Japan (marketed by partner Nippon Kayaku) and China (marketed by partner Innovent Biologics). IBTROZI is the company's only FDA-approved product and its near-term revenue depends on its U.S. commercial launch, while Nuvation's pipeline also includes safusidenib, an oral mIDH1 inhibitor in Phase 3 development, with both drugs originally licensed from Daiichi S